 In the last five years, advances in next-generation sequencing has really given us an opportunity to dramatically improve the treatment of cancer. We're no longer necessarily going after where the tissue starts. Who cares if it's breast, prostate, or lung? Ultimately, it's what's causing it, and that's what you get out of genetic sequencing. You understand the mutation that actually causes it, which creates an opportunity to block that mutation. By blocking cancer at its root, at its core cause, you can have dramatic benefit. You really can change effectiveness and safety for the patient.